drugset

drugset / Trial / NCT07390123

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

NCT07390123 ↗

Phase 3 Recruiting 370 enrolled Haisco Pharmaceutical Group Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN

Timeline

Start: 2026-04-07
Primary completion: 2027-12
Completion: 2028-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HSK39297	Unknown	200 mg	—

Indications